PURPOSE: The relation between tissue AGEs and mortality in end-stage renal disease (ESRD) is documented, but only in hemodialysis (HD) patients. This study aimed to measure and compare tissue AGEs levels in patients receiving either HD or peritoneal dialysis (PD) and to study the effect of these products on all-cause, cardiovascular or sepsis-related mortality. METHODS: Tissue AGEs were noninvasively assessed in 304 dialysis patients (202 on chronic HD and 102 on continuous ambulatory PD) by measuring skin autofluorescence using a validated Autofluorescence Reader (AGE Reader, DiagnOptics b.v., Groningen, The Netherlands). RESULTS: There was no difference in regard to AGEs levels between the HD (3.6 ± 0.8 AU)- and PD (3.5 ± 0.7 AU, p = 0.2)-treated patients. Diabetic patients had higher AGEs values in the HD group (3.97 ± 0.81 vs. 3.52 ± 0.77, p = 0.002), but not in the PD group (3.68 ± 0.6 vs. 3.45 ± 0.70, p = 0.26). In PD patients, increasing AGEs levels were associated with an elevated risk of all-cause mortality (a 2.09-fold increase for each increment of 1 AU in AGEs values) and sepsis (a 3.44-fold increase for each increment of 1 AU in AGEs values)-related mortality. Performing a similar analysis in diabetic patients, AGEs was associated only with sepsis-related mortality (a 3.08-fold increase for each increment of 1 AU in AGEs values). CONCLUSIONS: This is the first study that demonstrates a relationship between tissue AGEs levels and sepsis-related mortality in PD-treated or diabetic ESRD patients. Future studies are necessary to evaluate the non-cardiovascular effects of tissue AGEs in ESRD patients.
PURPOSE: The relation between tissue AGEs and mortality in end-stage renal disease (ESRD) is documented, but only in hemodialysis (HD) patients. This study aimed to measure and compare tissue AGEs levels in patients receiving either HD or peritoneal dialysis (PD) and to study the effect of these products on all-cause, cardiovascular or sepsis-related mortality. METHODS: Tissue AGEs were noninvasively assessed in 304 dialysis patients (202 on chronic HD and 102 on continuous ambulatory PD) by measuring skin autofluorescence using a validated Autofluorescence Reader (AGE Reader, DiagnOptics b.v., Groningen, The Netherlands). RESULTS: There was no difference in regard to AGEs levels between the HD (3.6 ± 0.8 AU)- and PD (3.5 ± 0.7 AU, p = 0.2)-treated patients. Diabeticpatients had higher AGEs values in the HD group (3.97 ± 0.81 vs. 3.52 ± 0.77, p = 0.002), but not in the PD group (3.68 ± 0.6 vs. 3.45 ± 0.70, p = 0.26). In PDpatients, increasing AGEs levels were associated with an elevated risk of all-cause mortality (a 2.09-fold increase for each increment of 1 AU in AGEs values) and sepsis (a 3.44-fold increase for each increment of 1 AU in AGEs values)-related mortality. Performing a similar analysis in diabeticpatients, AGEs was associated only with sepsis-related mortality (a 3.08-fold increase for each increment of 1 AU in AGEs values). CONCLUSIONS: This is the first study that demonstrates a relationship between tissue AGEs levels and sepsis-related mortality in PD-treated or diabetic ESRDpatients. Future studies are necessary to evaluate the non-cardiovascular effects of tissue AGEs in ESRDpatients.
Authors: S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy Journal: Nat Med Date: 2000-06 Impact factor: 53.440
Authors: Vedat Schwenger; Christian Morath; Alexander Salava; Kerstin Amann; Yuri Seregin; Reinhold Deppisch; Eberhard Ritz; Angelika Bierhaus; Peter P Nawroth; Martin Zeier Journal: J Am Soc Nephrol Date: 2005-11-30 Impact factor: 10.121
Authors: T Miyata; Y Wada; Z Cai; Y Iida; K Horie; Y Yasuda; K Maeda; K Kurokawa; C van Ypersele de Strihou Journal: Kidney Int Date: 1997-04 Impact factor: 10.612
Authors: Lisanne C de Vos; Douwe J Mulder; Andries J Smit; Robin P F Dullaart; Nanne Kleefstra; Willem M Lijfering; Pieter W Kamphuisen; Clark J Zeebregts; Joop D Lefrandt Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-13 Impact factor: 8.311
Authors: P J Beisswenger; Z Makita; T J Curphey; L L Moore; S Jean; T Brinck-Johnsen; R Bucala; H Vlassara Journal: Diabetes Date: 1995-07 Impact factor: 9.461
Authors: Christian Bopp; Angelika Bierhaus; Stefan Hofer; Axel Bouchon; Peter P Nawroth; Eike Martin; Markus A Weigand Journal: Crit Care Date: 2008-01-09 Impact factor: 9.097
Authors: Katarzyna Janda; Marcin Krzanowski; Mariusz Gajda; Paulina Dumnicka; Ewa Jasek; Danuta Fedak; Agata Pietrzycka; Marek Kuźniewski; Jan A Litwin; Władysław Sułowicz Journal: Dis Markers Date: 2015-03-17 Impact factor: 3.434
Authors: Ivan Cavero-Redondo; Alba Soriano-Cano; Celia Álvarez-Bueno; Pedro G Cunha; Jose A Martínez-Hortelano; Miriam Garrido-Miguel; Carlos Berlanga-Macías; Vicente Martínez-Vizcaíno Journal: J Am Heart Assoc Date: 2018-09-18 Impact factor: 5.501